Gilead enters into licensing agreement with biotech company

US-based Gilead announced Tuesday, September 4 that it has entered into a licensing agreement with biotech company Trianni for an undisclosed sum.

Under the terms of the agreement, Gilead will be able to use Trianni’s transgenic human monoclonal antibody discovery platform to help bolster drug discovery.

Bill Lee, executive vice president of research at Gilead, said that the company is looking forward to integrating Trianni’s technologies into Gilead’s own research and development programme.

“This platform will help enhance our ability to discover human antibodies and to develop new therapies in areas of unmet medical need.”

US-based Trianni is a biotech company that specialises in discovery technology.

Its main technology is a “next-generation transgenic discovery platform” that is designed to leverage developments in DNA synthesis and genomic modification technology.

Matthias Wabl, president and CEO of Trianni, said the company is pleased that Gilead has chosen to use Trianni’s discovery platform.

“We are confident that the cutting-edge genomic design of the Trianni discovery platform, which combines the complete human antibody repertoire with wild-type mouse immune responses to any target antigen, will nicely complement Gilead’s drug discovery programmes,” he said.

The topic of antibodies will be discussed at the Life Sciences Patent Network North America Fall conference on October 16 in San Francisco. To find out more, click  here.

Did you enjoy reading this story?  Sign up to our free daily newsletters and get stories sent like this straight to your inbox.